Antimicrobial resistance is a $100T problem.

Aikya connects fragmented global evidence to always-on agentic infrastructure, optimising drug discovery and bridging the laboratory funding gap to secure a pool of promising assets for long-term human safety.

Sector Alert: 6,304 C. auris clinical cases verified in Sector-US (Cycle: 2024).